InspireMD (NYSE:NSPR) Director Paul Stuka Acquires 10,000 Shares of Stock

Posted by Geri Gentry on May 13th, 2026

InspireMD, Inc. (NYSE:NSPR – Get Free Report) Director Paul Stuka acquired 10,000 shares of InspireMD stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $1.19 per share, for a total transaction of $11,900.00. Following the transaction, the director owned 632,871 shares of the company’s stock, valued at $753,116.49. This represents a 1.61% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

On Friday, May 8th, Paul Stuka acquired 65,626 shares of InspireMD stock. The shares were bought at an average price of $1.16 per share, for a total transaction of $76,126.16.
On Thursday, May 7th, Paul Stuka acquired 6,378 shares of InspireMD stock. The shares were bought at an average price of $1.15 per share, for a total transaction of $7,334.70.
On Wednesday, May 6th, Paul Stuka bought 1,517 shares of InspireMD stock. The shares were acquired at an average cost of $1.12 per share, with a total value of $1,699.04.

InspireMD Stock Down 4.0%

NYSE:NSPR opened at $1.20 on Wednesday. InspireMD, Inc. has a 52 week low of $1.02 and a 52 week high of $2.93. The company has a market capitalization of $56.21 million, a P/E ratio of -1.60 and a beta of 0.82. The stock’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.73.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on NSPR shares. Lake Street Capital set a $4.00 target price on InspireMD in a research report on Monday, May 4th. Loop Capital set a $5.00 price objective on InspireMD in a research note on Tuesday, February 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Finally, Maxim Group initiated coverage on InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 target price for the company. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, InspireMD currently has a consensus rating of “Buy” and a consensus price target of $4.50.

Get Our Latest Report on NSPR

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NSPR. XTX Topco Ltd purchased a new stake in shares of InspireMD in the 4th quarter valued at about $30,000. Virtu Financial LLC purchased a new stake in shares of InspireMD in the 4th quarter valued at about $31,000. Creative Planning purchased a new stake in shares of InspireMD in the 2nd quarter valued at about $44,000. Legato Capital Management LLC purchased a new stake in shares of InspireMD in the 4th quarter valued at about $48,000. Finally, Uniting Wealth Partners LLC purchased a new stake in InspireMD during the 3rd quarter valued at approximately $51,000. 44.78% of the stock is owned by institutional investors and hedge funds.

About InspireMD

(Get Free Report)

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.